rafoxanide has been researched along with Colorectal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, S; Colantoni, A; Colella, M; Di Fusco, D; Di Grazia, A; Franzè, E; Laudisi, F; Luiz-Ferreira, A; Maresca, C; Monteleone, G; Monteleone, I; Ortenzi, A; Pacifico, T; Sica, GS; Stolfi, C | 1 |
| Cherubini, F; Colantoni, A; De Simone, V; Di Fusco, D; Di Grazia, A; Dinallo, V; Fearon, ER; Franzè, E; Laudisi, F; Monteleone, G; Monteleone, I; Ortenzi, A; Stolfi, C | 1 |
2 other study(ies) available for rafoxanide and Colorectal Neoplasms
| Article | Year |
|---|---|
Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Humans; Rafoxanide; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2022 |
Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide.
Topics: Aged; Animals; Antinematodal Agents; Apoptosis; Azoxymethane; Carcinogens; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Endoplasmic Reticulum Stress; Female; Humans; Male; Mice; Rafoxanide; Tumor Cells, Cultured | 2019 |